3.51
-0.18 (-4.88%)
| Previous Close | 3.69 |
| Open | 3.71 |
| Volume | 13,698 |
| Avg. Volume (3M) | 22,864 |
| Market Cap | 1,884,600 |
| Price / Book | 0.330 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2025 - 31 Mar 2025 |
| Diluted EPS (TTM) | -105.78 |
| Total Debt/Equity (MRQ) | 6.74% |
| Current Ratio (MRQ) | 6.10 |
| Operating Cash Flow (TTM) | -8.06 M |
| Levered Free Cash Flow (TTM) | -2.56 M |
| Return on Assets (TTM) | -62.40% |
| Return on Equity (TTM) | -149.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | ENDRA Life Sciences Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | -0.17 |
|
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 0.14% |
| % Held by Institutions | 0.02% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | Announcement | ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies |
| 31 Mar 2025 | Announcement | ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |